Savara And PANTHERx Rare Pharmacy Announce An Exclusive Distribution Agreement For MOLBREEVI

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was requested.

If approved, PANTHERx and its team of rare care experts will be responsible for the dispensing and distribution of MOLBREEVI in the U.S and will leverage its proprietary RxARECARE® model to deliver highly specialized rare disease patient and prescriber support services, including clinical case management, disease and therapy education, and comprehensive financial and insurance assistance.

"Our selection of PANTHERx as the exclusive U.S. specialty pharmacy for MOLBREEVI underscores Savara's commitment to delivering more than a medicine—we will be delivering a complete care experience for patients," said Braden Parker, Chief Commercial Officer, Savara. "This partnership reflects our shared mission to improve the lives of patients with autoimmune PAP by making their journey to therapy as smooth and supportive as possible."

MOLBREEVI, a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), is an inhaled investigational medicine being developed for autoimmune PAP, a rare and chronic lung disease caused by GM-CSF autoantibodies which block GM-CSF signaling and reduce surfactant clearance—resulting in difficulty breathing and, ultimately, hypoxemic respiratory failure. MOLBREEVI, administered via a proprietary eFlow® Nebulizer System (PARI Pharma GmbH) is believed to help restore the surfactant-clearing activity of macrophages, thus improving oxygenation, lung function, and health-related quality of life (HRQoL).

"We are proud to partner with Savara to support the launch of MOLBREEVI and help ensure eligible patients with autoimmune PAP receive timely access and ongoing engagement throughout their treatment journey," said Bansi Nagji, CEO of PANTHERx. "By driving therapy adherence and persistence, PANTHERx will work with Savara to help optimize outcomes for individuals living with autoimmune PAP through our proven care model. 95.45% of the patients served by PANTHERx have no unresolved barriers at their annual assessment1, and we are committed to delivering that same level of success to this community."